Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

2.5K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.5K
Drug Therapy01:28

Drug Therapy

445
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
445
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

699
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
699
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

972
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
972
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From dysbiosis to metabolic vulnerability: implications for precision psychiatry in depression.

Molecular psychiatry·2026
Same author

Toward a systems model of catatonia: Circuits, neurochemistry, immune perturbation, and biological heterogeneity.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same author

Hospital-treated infection associated with Alzheimer's disease pathology: underlying mechanisms.

Molecular psychiatry·2026
Same author

Rethinking Parkinson's disease genetics in the precision medicine era: why genomic diversity matters?

Frontiers in genetics·2026
Same author

Closing the Evidence Gap in Catatonia: A Call for Comparative Trials of Benzodiazepines and Electroconvulsive Therapy.

The journal of ECT·2026
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Apr 28, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.9K

Emerging Therapeutic Interventions for Treatment‑Resistant Depression.

Marcela Carbajal Tamez1, Giselli Scaini2, Joao Quevedo2

  • 1Center for Interventional Psychiatry, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA. Marcela.C.CarbajalTamez@uth.tmc.edu.

Advances in Experimental Medicine and Biology
|April 26, 2026
PubMed
Summary

Treatment-resistant depression (TRD) requires novel strategies beyond traditional monoaminergic targets. Experimental developments show promise for new TRD management, focusing on precision psychiatry and computational tools.

Keywords:
DepressionExperimentalMajor Depressive DisorderNovel InterventionsPersonalized MedicineTreatment-Resistant Depression

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:19

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

200

Related Experiment Videos

Last Updated: Apr 28, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.9K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:19

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

200

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Treatment-resistant depression (TRD) is a significant clinical challenge.
  • TRD presents a distinct neurobiological syndrome within affective disorders.
  • Current pharmacotherapy primarily targets monoaminergic systems.

Purpose of the Study:

  • To outline progress in therapeutic strategies for TRD.
  • To highlight translational models, precision psychiatry, and computational tools.
  • To disseminate promising experimental developments for TRD management.

Main Methods:

  • Review of translational models.
  • Analysis of precision psychiatry approaches.
  • Exploration of computational tools in TRD research.

Main Results:

  • Growing mechanistic insights into TRD beyond monoaminergic systems.
  • Feasibility of precision interventions is increasing.
  • Experimental developments show promise in preclinical studies.

Conclusions:

  • Novel therapeutic strategies for TRD are emerging.
  • Precision interventions face constraints in clinical trial design and access.
  • Further research into experimental developments is needed to inspire new TRD management strategies.